All In Biotech

Drug Trial Radar · NCT01482104

New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)

A Randomized Controlled Blinded Multi-centre Study of Photodynamic Therapy With Methyl-aminolevulinate Comparing a Simplified Regime With the Approved Regime in Patients With Clinical Low-risk Superficial and Nodular Basal Cell Carcinoma.

Last checked: Nov 20, 2026Latest source record: Oct 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 277 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

277

Actual

Start

Jun 2012

Primary completion

Oct 2017

Study completion Oct 2017

Sponsor

Lead sponsor
Norwegian University of Science and TechnologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Akershus Dermatological Centre; Helse Stavanger HF; Oslo University Hospital; Førde Central Hospital; Haukeland University Hospital; Hudlegekontoret Lillehammer; Hudlegene på Holtet DA
First posted
Nov 30, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Basal cell carcinoma (BCC) is the most common malignant skin lesion in white adults. It is a slow-growing tumour which despite low metastatic potential may cause significant local tissue destruction and patient morbidity. Methyl aminolevulinate cream plus photodynamic therapy (MAL-PDT) for BCC is currently approved for a procedure using 2 treatment sessions 1 week apart. This procedure is considered quite time- and resource-consuming. Introducing a single treatment session, with a new PDT session for treatment failures after 3 months, might represent an attractive simplification. This randomised controlled single-blinded multi-centre study primarily aims to compare BCC lesion response rate of two treatment schedules: (a) 1 single treatment of Metvix-PDT with re-treatment of non-complete responders by 3 months, and (b) the usual schedule of 2 standard Metvix(R) PDT treatments 1 week apart. Secondary objectives are to investigate the treatment response in relation to clinical and histological tumour characteristics such as tumour thickness, subtype and immunohistochemical markers.

Conditions

  • Skin Neoplasms
  • Carcinoma, Basal Cell

Interventions

  • MAL-PDT re-treatmentDrug

    a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months

  • usual MAL-PDTDrug

    schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. lesions response rateTime frame: 3 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Dept Dermatology, Haukeland University Hospital

    Bergen, Norway

  • Central Hospital Førde

    Førde, Norway

  • Hudlegekontoret Lillehammer AS

    Lillehammer, Norway

  • Akerskus Dermatological Centre

    Lørenskog, Norway

  • Dept Dermatology, Oslo University Hospital

    Oslo, Norway

  • Dept Surgery, Oslo University Hospital

    Oslo, Norway

  • Hudlegen på Holtet

    Oslo, Norway

  • Dept Dermato-Venereology, Stavanger University Hospital

    Stavanger, Norway

  • Department of Cancer Research and Molecular Medicine, NTNU

    Trondheim, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.